Nature Search

Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019

Chronic care manages long-term, progressive conditions, while acute care handles short-term ones. Here, authors show chronic conditions account for most of the global health burden, with 68% of DALYs and 93% of YLDs attributed to chronic care needs.

Cecilia Anza-Ramirez
J. Jaime Miranda
Yves Miel H. Zuniga
ResearchOpen Access07 May 2025
Nature Communications

Volume: 16, P: 1-36
The influence of HLA genetic variation on plasma protein expression

Genetic variation in the HLA locus is associated with many traits, including autoimmune diseases. Here, the authors show that HLA genetic variation exerts widespread trans effects on plasma protein expression, aiding interpretation of associations between HLA alleles and immune mediated diseases.

Chirag Krishna
Joshua Chiou
Xinli Hu
ResearchOpen Access31 Jul 2024
Nature Communications

Volume: 15, P: 1-15
Comparative evaluation of phytochemical, nutritional, in vitro antioxidant and anti-inflammatory properties of cold pressed oils in India

Prathap V
Suresh K
Sanafrian S
ResearchOpen Access10 Nov 2025
Scientific Reports

Volume: 15, P: 1-17
Author Correction: Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies

Emily R. Kansler
Saïda Dadi
Ming O. Li
Amendments and Corrections15 Jun 2022
Nature Immunology

Volume: 23, P: 1285
Terminal differentiation and persistence of effector regulatory T cells essential for preventing intestinal inflammation

The authors show that terminally differentiated colonic T_reg cells are required for maintaining colonic health and, although these cells are major producers of this cytokine, IL-10 is dispensable for their suppressive function.

Stanislav Dikiy
Aazam P. Ghelani
Alexander Y. Rudensky
ResearchOpen Access04 Feb 2025
Nature Immunology

Volume: 26, P: 444-458
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy

Samstein et al. report that mutations in BRCA1 and BRCA2 result in distinct mutational genomic landscapes, effects on the tumor-immune microenvironment and response to immune checkpoint therapy.

Robert M. Samstein
Chirag Krishna
Nadeem Riaz
Research16 Nov 2020
Nature Cancer

Volume: 1, P: 1188-1203
Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab

In this biomarker cohort analysis of CheckMate 153, analyses of genomic alterations and neoepitope immunogenicity in tumor tissue samples from patients with non-small cell lung cancer treated with nivolumab show the evolution of neoantigens during nivolumab-induced selection pressure and how it associates with clinical response.

Tyler J. Alban
Nadeem Riaz
Timothy A. Chan
Research30 Sept 2024
Nature Medicine

Volume: 30, P: 3209-3222
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types

A combination of genomic and clinical features improves predictions of response to immune checkpoint blockade.

Diego Chowell
Seong-Keun Yoo
Timothy A. Chan
Research01 Nov 2021
Nature Biotechnology

Volume: 40, P: 499-506
Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies

How the immune system responds to epithelial cancers beyond neoantigen-driven adaptive immunity is poorly understood. Kansler et al. reveal an innate immune surveillance response mediated by cytotoxic ILC1 sensing of cancer cell-expressed IL-15.

Emily R. Kansler
Saïda Dadi
Ming O. Li
Research26 May 2022
Nature Immunology

Volume: 23, P: 904-915
Programme of self-reactive innate-like T cell-mediated cancer immunity

A survey of T cell populations in human and mouse tumours identifies a population of cancer-sensing IL-15-activated αβ T cell receptor-positive FCER1G-expressing innate-like T cells with high cytotoxic potential.

Chun Chou
Xian Zhang
Ming O. Li
Research20 Apr 2022
Nature

Volume: 605, P: 139-145
Mouse cytomegalovirus-experienced ILC1s acquire a memory response dependent on the viral glycoprotein m12

O’Sullivan and colleagues show that liver-resident type 1 ILCs have enhanced protective effector responses to secondary challenge with mouse cytomegalovirus, dependent on the viral glycoprotein m12.

Orr-El Weizman
Eric Song
Timothy E. O’Sullivan
Research01 Jul 2019
Nature Immunology

Volume: 20, P: 1004-1011
Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy

The degree of sequence divergence between patient MHC class I alleles influences the response to immune checkpoint blockade therapy independently of tumor mutational burden.

Diego Chowell
Chirag Krishna
Timothy A. Chan
Research07 Nov 2019
Nature Medicine

Volume: 25, P: 1715-1720
Immunogenic neoantigens derived from gene fusions stimulate T cell responses

Fusion proteins in cancers with low mutational burden represent functional neoantigens that elicit T cell activation and mediate responses to immunotherapy.

Wei Yang
Ken-Wing Lee
Luc G. T. Morris
Research22 Apr 2019
Nature Medicine

Volume: 25, P: 767-775
The Consortium on Vulnerability to Externalizing Disorders and Addictions (c-VEDA): an accelerated longitudinal cohort of children and adolescents in India

Yuning Zhang
Nilakshi Vaidya
Bhavana B R
Reviews12 Mar 2020
Molecular Psychiatry

Volume: 25, P: 1618-1630

Search

Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019

The influence of HLA genetic variation on plasma protein expression

Comparative evaluation of phytochemical, nutritional, in vitro antioxidant and anti-inflammatory properties of cold pressed oils in India

Author Correction: Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies

Terminal differentiation and persistence of effector regulatory T cells essential for preventing intestinal inflammation

Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy

Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab

Improved prediction of immune checkpoint blockade efficacy across multiple cancer types

Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies

Programme of self-reactive innate-like T cell-mediated cancer immunity

Mouse cytomegalovirus-experienced ILC1s acquire a memory response dependent on the viral glycoprotein m12

Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy

Immunogenic neoantigens derived from gene fusions stimulate T cell responses

The Consortium on Vulnerability to Externalizing Disorders and Addictions (c-VEDA): an accelerated longitudinal cohort of children and adolescents in India

Search

Quick links

Search

Filter By:

Search

Quick links